The abstract is read at the publisher; the summary is JClub's.
CHARGE direct-contact cascade testing increased relative-reported testing to 53% (8/15) versus 22% (2/9) in usual care, with adjusted odds ratio 7.7 (95% CI 1.1–54.3).
- Why it matters: Cascade genetic testing is more effective with direct contact, but real-world uptake is constrained by unaddressed testing costs and limited implementation evidence.
- What they did: In a randomized hybrid type I effectiveness–implementation feasibility trial, eligible relatives were randomized at the proband level to CHARGE (direct contact plus education about a free testing window) or usual care, with mixed-methods evaluation.
- The result: CHARGE was feasible and acceptable, reaching 23% (28/122) of eligible probands and showing higher odds of testing for intervention relatives than controls (P = .04), suggesting integrated recruitment may be needed.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.